中国循证医学杂志

中国循证医学杂志

活血化瘀药物防治冠心病:循证与展望

查看全文

活血化瘀防治心血管疾病的理论创新与新药研究,是我国中西医结合领域六十余年来研究最为活跃、成果最为突出的标志性成就之一。“血瘀证与活血化瘀研究”曾获得建国以来第一个中医药领域的国家科学技术进步一等奖。六十余年来,以陈可冀院士为首的研究团队,以临床重大心血管疾病—冠心病为切入点,在“血瘀证”病证结合诊断标准的制定、“活血化瘀”现代内涵的阐释、系列活血化瘀中药新药的研发、临床疗效评价及作用机制探究等方面获得了丰厚成果,推动了传统中医药的标准化和国际化进程,形成了高质量的临床转化应用证据,为心血管疾病的中医药防治做出了突出贡献。本文回顾了建国后活血化瘀疗法防治心血管疾病的历史,重点阐述了国内多个学术团队六十余年来代表性的研究成果,以期为推动、创新活血化瘀研究提供参考。

The theoretical innovation and new drug research on the prevention and treatment of cardiovascular diseases by activating blood circulation has been one of the most active and outstanding achievements in the field of integrated Chinese and western medicine for the past 60 years. Research on blood stasis syndrome (BSS) and activating blood circulation (ABC) was the first to be awarded the first prize of National Award for Science and Technology Progress in Chinese Medicine since the founding of the People's Republic of China. The research team headed by prof. Keji CHEN has obtained abundant research achievements. Taking coronary heart disease, a major clinical cardiovascular disease as the entry point, the team explored the development of the diagnostic criteria for the combination of BSS, the interpretation of the modern connotation of ABC, the development of a series of new drugs for ABC, clinical efficacy evaluation and mechanism of its action. It promotes the standardization and internationalization of traditional Chinese medicine and forms high-quality evidence for clinical transformation. It has also made outstanding contributions to the prevention and treatment of cardiovascular diseases with original features. In this paper, the history of prevention and treatment of cardiovascular diseases by ABC after the founding of the People's Republic of China was reviewed. The representative research findings of several domestic academic teams, including prof. Keji CHEN's team, over the past 60 years were expounded emphatically so as to provide reference for promoting and innovating research in activating blood circulation and removing blood stasis.

关键词: 活血化瘀; 血瘀证; 冠心病; 循证医学

Key words: Activating blood circulation; Blood stasis syndrome; Coronary heart disease; Evidence-based medicine

引用本文: 刘玥, 高铸烨, 付长庚, 徐浩, 史大卓, 陈可冀. 活血化瘀药物防治冠心病:循证与展望. 中国循证医学杂志, 2018, 18(11): 1145-1150. doi: 10.7507/1672-2531.201809110 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. 卫生部心血管病防治研究中心. 中国心血管病报告 2017. 北京: 中国大百科全书出版社, 2018.
2. 陈可冀, 陈贵廷, 张问渠. 日本活血化瘀研究进展. 中国中西医结合杂志, 1985, 5(3): 185-189, 174.
3. 史载祥. 韩国学者在血瘀证及其治疗方面的新进展. 中国中西医结合杂志, 1998, 18(5): 307.
4. 北京地区防治冠心病协助组. 冠心Ⅰ号、Ⅱ号方(活血化瘀途径)治疗冠心病心绞痛的初步报告. 内部资料, 1972.
5. 陈可冀, 钱振淮, 张问渠, 等. 精制冠心片双盲法治疗冠心病心绞痛 112 例疗效分析. 中华心血管病杂志, 1982, 10(2): 85-89.
6. 聂阳, 焦豪妍, 何盛江, 等. 基于多指标综合评价优选乐脉颗粒提取工艺. 中药新药与临床药理, 2016, 27(2): 273-277.
7. 乔雪, 徐曼, 韩健, 等. 中药复方冠心Ⅱ号的化学成分及药理研究进展. 世界科学技术-中医药现代化, 2007, 9(3): 86-95, 106.
8. 中医研究院西苑医院内科(陈可冀, 等). 川芎一号碱(川芎嗪)对冠心病患者血小板影响的电子显微镜观察. 中华内科杂志, 1976, 2: 89-91.
9. Chang FC, Chen KJ, Lin JG, et al. Effects of tetramethylpyrazine on portal hypertensive rats. J Pharm Pharmacol, 1998, 50(8): 881-884.
10. 陈可冀. 川芎嗪的化学、药理与临床应用. 北京: 人民卫生出版社, 1999.
11. 陈可冀. 川芎嗪的化学、药理与临床应用(第二版). 北京: 人民卫生出版社, 2014.
12. 高洁. 川芎嗪调控相关 microRNAs 干预冠心病血栓前状态的研究. 北京: 北京中医药大学, 2018.
13. 雷燕, 刘建勋, 周亚伟, 等. 愈心痛胶囊对急性心肌缺血犬血浆内皮素和血清一氧化氮的影响. 中国中西医结合杂志, 1996, 16(5): 289-291.
14. 雷燕, 陈可冀, 柯元南, 等. 愈心痛胶囊治疗不稳定性心绞痛临床研究. 中国中西医结合杂志, 1996, 16(10): 580-584.
15. Qiu Y, Xu H, Shi D. Traditional chinese herbal products for coronary heart disease: an overview of cochrane reviews. Evid Based Complement Alternat Med, 2012, 2012: 417387.
16. Duan X, Zhou L, Wu T, et al. Chinese herbal medicine suxiao jiuxin wan for angina pectoris. Cochrane Database Syst Rev, 2008, (1): CD004473.
17. 史大卓, 李静, 马晓昌, 等. 血府逐瘀浓缩丸预防冠心病病人经皮冠状动脉腔内成形术后再狭窄的临床观察. 中医杂志, 1997, (1): 27-29, 4.
18. 王伟, 马晓昌, 汪晓芳, 等. 精制血府胶囊治疗冠心病心绞痛 30 例临床观察. 中医杂志, 2000, (8): 471-473, 478.
19. 汪晓芳, 陈可远, 王伟, 等. 精制血府胶囊治疗冠心病心绞痛的临床研究. 中国中西医结合杂志, 1998, 18(7): 399-401.
20. 徐凤芹, 史大卓, 陈可冀, 等. 精制血府胶囊对犬急性心肌缺血心脏血流动力学和心肌耗氧量的影响. 中国中西医结合杂志, 1998, 18(1): 32-34.
21. 王伟, 史大卓, 陈可冀, 等. 精制血府胶囊刺激缺氧缺糖心肌细胞 RNA 及蛋白质合成的研究. 北京中医药大学学报, 1997, (2): 18-20, 71.
22. 徐浩, 史大卓, 陈可冀, 等. 芎芍胶囊对猪冠状动脉球囊损伤后血管重塑的影响. 中国中西医结合杂志, 2001, 21(8): 591-594.
23. Chen KJ, Shi DZ, Xu H, et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J (Engl), 2006, 119(1): 6-13.
24. Zheng GH, Liu JP, Chu JF, et al. Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease. Cochrane Database Syst Rev, 2013, (5): CD009581.
25. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med, 2011, 17(10): 1217-1220.
26. Wang SL, Wang CL, Wang PL, et al. Combination of Chinese herbal medicines and conventional treatment versus conventional treatment alone in patients with acute coronary syndrome after percutaneous coronary intervention (5c trial): an open-label randomized controlled, multicenter study. Evid Based Complement Alternat Med, 2013, 2013: 741518.
27. Zhang L, Li Y, Yang BS, et al. A multicenter, randomized, double-blind, and placebo-controlled study of the effects of tongxinluo capsules in acute coronary syndrome patients with high on-treatment platelet reactivity. Chin Med J (Engl), 2018, 131(5): 508-515.
28. 董静, 陈韵岱, 智光, 等. 应用速度向量成像技术评价丹红注射液的 PCI 围术期心肌保护作用. 中华医学杂志, 2014, 94(30): 2346-2349.
29. 胡国英, 毛燕玲, 王秀君, 等. 抗心梗合剂对心肌梗塞病人血小板聚集功能的变化(摘要). 心肺血管病杂志, 1983, (1): 15-16.
30. 翁心植, 赵荔雍, 陈鼎祺. 抗心梗合剂治疗急性心肌梗塞的疗效总结(摘要). 心肺血管病杂志, 1982, (1): 5.
31. 廖欣, 罗陆一. 愈梗通瘀汤治疗冠心病心绞痛的临床观察. 中国中西医结合杂志, 1998, 18(10): 594-597.
32. 李思铭. 愈梗通瘀汤对急性心肌梗死早期预后及生活质量影响的临床研究. 北京: 北京中医药大学, 2011.
33. Shang H, Zhang J, Yao C, et al. Qi-shen-yi-qi dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial. Evid Based Complement Alternat Med, 2013, 2013: 738391.
34. 尤士杰, 陈可冀, 杨跃进, 等. 通心络胶囊干预急性心肌梗死早期血运重建后自发性改善的临床研究. 中国中西医结合杂志, 2005, 25(7): 604-607.
35. 徐浩, 史大卓, 殷惠军. " 瘀毒致变”与急性心血管事件: 假说的提出与临床意义. 中国中西医结合杂志, 2008, 28(10): 934-938.
36. 史大卓, 徐浩, 殷惠军, 等. " 瘀”、" 毒”从化—心脑血管血栓性疾病病因病机. 中西医结合学报, 2008, 6(11): 1105-1108.
37. Li S, Guo M, Mao H, et al. Qing-Xin-Jie-Yu Granules in addition to conventional treatment for patients with stable coronary artery disease (QUEST Trial): study protocol for a randomized controlled trial. Trials, 2016, 17(1): 451.
38. 李金根. 清心解瘀方对稳定性冠心病临床终点事件影响的随机双盲对照研究. 北京: 北京中医药大学, 2018.
39. 陈可冀. 现代活血化瘀学派的传承创新发展轨迹. 中国中西医结合杂志, 2015, 35(12): 1413-1414.
40. 中国中西医结合研究会活血化瘀专业委员会. 血瘀证诊断标准. 中西医结合杂志, 1987, 7(3): 129.
41. 中国中西医结合学会活血化瘀专业委员会, 陈可冀, 徐浩, 等. 实用血瘀证诊断标准. 中国中西医结合杂志, 2016, 36(10): 1163.
42. 中国中西医结合学会活血化瘀专业委员会, 陈可冀, 史大卓, 等. 冠心病血瘀证诊断标准. 中国中西医结合杂志, 2016, 36(10): 1162.
43. 陈可冀, 史大卓. 冠心病及急性心肌梗死中医临床辨证标准及防治指南. 北京: 人民卫生出版社, 2014.
44. 急性心肌梗死中西医结合诊疗指南. 中国中西医结合杂志, 2018, 38(3): 272-284.
45. 刘红旭, 吴永健, 王显, 等. 经皮冠状动脉介入治疗围手术期心肌损伤中医诊疗专家共识. 中国中西医结合杂志, 2017, 37(4): 389-393.
46. 付长庚, 刘龙涛, 王跃飞, 等. 丹红注射液临床应用中国专家共识. 中国中西医结合杂志, 2018, 38(4): 389-397.
47. 刘龙涛, 付长庚. 脑心通胶囊临床应用中国专家共识. 中国中西医结合杂志, 2017, 37(9): 1039-1042.
48. 陈可冀, 付长庚, 丛伟红, 等. 红花黄色素临床应用中国专家共识. 中国中西医结合杂志, 2017, 37(10): 1167-1173.
49. 刘玥, 殷惠军, 史大卓, 等. 活血化瘀中药与抗血小板治疗. 科学通报, 2014, 59(8): 647-655.
50. 陈可冀, 刘玥. 多效药片与心血管疾病的预防: 证据、评价与思考. 中国循证医学杂志, 2015, 15(7): 745-748.
51. 吴泰相, 卞兆祥, 商洪才, 等. 从中药复方临床随机对照试验报告规范 2017: CONSORT声明的扩展、说明与详述的正式发表谈我国临床试验的变革. 中国循证医学杂志, 2017, 17(9): 993-998.
52. Tian PP, Li J, Gao J, et al. Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial. BMJ Open, 2018, 8(2): e018052.
53. Wang PQ, Li DD, Dong W, et al. Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial. Trials, 2015, 16: 474.
54. 胡嘉元, 张晓雨, 赵晨, 等. 母方案设计用于冠心病中医药防治方案循证优化的思路和实施方法. 中国循证医学杂志, 2018, inpress.
55. 姜众会, 孟闫燕, 杨巧宁, 等. 冠心病中西药联用交互作用分析方法的思考. 世界中医药, 2017, 12(12): 3179-3181.
56. 刘艳飞, 孙明月, 赵莹科, 等. 网络药理学在中药药物重定位研究中的应用现状与思考. 中国循证医学杂志, 2017, 17(11): 1344-1349.